Cannabis Medicines: Balancing Therapeutic Benefits Against Side Effects and Abuse Potential | Research

The takeaway

A review of cannabis-derived pharmaceuticals noted that while THC-based medicines are clinically useful for nausea, appetite, MS, and glaucoma, their side effects and abuse potential remain limitations, driving interest in endocannabinoid system modulators as alternatives.

Read this if you want an overview of the benefits and limitations of existing cannabis-based medications.

Side effects and abuse liability limit THC-based medicines despite proven therapeutic applications

What the researchers found

This review covered the pharmacology, therapeutic uses, and toxicology of cannabis-derived medications.

Existing clinical applications included Sativex (THC/CBD extract) for MS symptoms, nabilone and dronabinol for chemotherapy-induced nausea, and dronabinol for appetite stimulation. THC extracts had also been used for glaucoma.

However, the severe side effects and high abuse liability of THC-based agents represented serious limitations. Diversion for recreational use was also a concern.

The review highlighted emerging alternatives: synthetic cannabinoid receptor agonists and agents that activate the endocannabinoid system indirectly (FAAH and MAGL inhibitors), which were being developed with the hope of providing therapeutic effects with better safety profiles.

Why it matters

This review captured the tension between the therapeutic potential and practical limitations of cannabis-based medicines, and the search for safer alternatives that maintain efficacy.

The numbers in context

Clinical cannabinoid medicines reviewed: Sativex, nabilone, dronabinol. Key concern areas: side effects, abuse liability, diversion risk.

How the study worked

Narrative review of recent studies and patents focused on cannabinoid system agonists for CNS disorders.

What this study cannot tell us

Narrative review without systematic methodology. Focus on agonists may have underrepresented other approaches. Some therapeutic claims were based on limited clinical evidence.

How to read the evidence

Narrative review providing a balanced overview of the therapeutic landscape but without systematic quality assessment.

When this study was published

Published in 2010. The cannabinoid pharmaceutical landscape has expanded since then, with Epidiolex (CBD) receiving FDA approval in 2018.

The bigger picture

The challenge of developing cannabinoid medicines that provide therapeutic benefits without psychoactive effects and abuse potential has driven research into indirect endocannabinoid system modulation rather than direct receptor activation.

Questions still open

Will indirect endocannabinoid modulators prove safer than direct agonists in clinical use? Can abuse liability be separated from therapeutic effects? Are plant-derived or synthetic cannabinoids preferable for clinical development?

Common questions

What cannabis medicines are approved for clinical use?

At the time of this review: dronabinol and nabilone for chemotherapy nausea, dronabinol for appetite stimulation, and Sativex for MS symptoms. CBD (Epidiolex) was later approved in 2018 for certain epilepsy types.

Why are researchers developing alternatives to THC medicines?

THC produces psychoactive effects, can be abused, and has significant side effects. Drugs that boost the body's own endocannabinoids (through FAAH or MAGL inhibition) may provide therapeutic benefits with fewer psychoactive effects and lower abuse potential.

Read the original research

Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.

Recent patents on CNS drug discovery, 5(1), 46-52

View on PubMed ↗

Citation

Gerra, Gilberto; Zaimovic, Amir; Gerra, Maria L; Ciccocioppo, Roberto; Cippitelli, Andrea; Serpelloni, Giovanni; Somaini, Lorenzo. (2010). Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.. Recent patents on CNS drug discovery, 5(1), 46-52.